Clinical Immunoanalyzer Markets

Clinical immunoanalyzer analysis is one of the most important functions of clinical laboratory analysis. By all accounts, automated immunoassay testing is the most rapidly developing of the traditional clinical laboratory sectors. Clinical immunoanalyzer analysis usually refers to determining the concentration or activity of protein, carbohydrate, lipid, enzyme or small molecule in easily collected body fluids, such as blood, serum, plasma or urine. However, it is not necessarily limited to these purposes. The analysis of virtually any biologically active substance in any place in the body can generally be defined as clinical immunoassay testing. In fact, traditional specialization barriers, such as microbiology, hematology, blood banking, immunology and even anatomical pathology are fading rapidly, both operationally and instrumentally. This TriMark Publications report deals with the traditional scope of clinical immunoassay, while looking at the emerging technology trends in this sector. The purpose of this study is to describe the specific segments of the global clinical immunoanalyzer instrumentation market. Within this area, the highly-active segments in terms of innovation and growth are covered. Specifically, it examines the markets for small labs and highly-automated large lab platforms, as well as the market for accessory equipment, such as reagents and supplies. Emphasis is on those companies and products that are actively developing and marketing immunoanalyzer products for clinical setting, including hospitals, independent labs, physician' s offices and clinics.

• Complete analysis of the major sectors of the clinical immunoanalyzer instrumentation market, their size, growth rates and major drivers.
• Presentation of some of the emerging technology platforms, elucidating the potential areas that could gain traction in this market.
• Analysis of the partnerships and alliances that various key sector players have forged, including the financing linkages of these market participants, apart from insights into potential market collaborations.
• Examination of new technology platforms in the U.S., Japan and Europe that seek to dominate this mature market.

The information and analysis presented in this review are based on an extensive survey of the clinical immunoanalyzer segment of the diagnostic instrumentation sector, as well as on a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, trade associations, and national and world health organizations. Key information from business literature was used to conduct dialog with and obtain expert opinion from market professionals regarding commercial potential and market size. Part of the information in this study is based on interviews with senior managers from major diagnostic companies.

This examination also relies upon information garnered through interviews with sales and marketing professionals of companies in the clinical analyzer market. People from virtually every company mentioned in this report were required, some of them several times, about their companies' products and marketing strategies as well as their overall thoughts about the industry. Information was also obtained from interviews with founders, chief executive officers and vice presidents of some companies. Information related to the structure of hospital laboratories and near-patient facilities was derived from interviews with laboratory directors and medical technologists working in those areas.

Other sources of information for the study were trade association publications and meetings, product brochures and catalogs, and company literature. Where the companies under discussion were publicly held, an examination of the annual reports, 10k filings and financial reports were used as the basis of the data reported. Important data sources include the Health for All Database of the World Health Organization, data published by the statistical office of the European Commission (Eurostat), as well as various health data from the United Nations and the Organization for Economic Co-operation and Development (OECD). Where possible and practicable, the most recent data available have been used.

The author of this report is a PhD in biochemistry with decades of experience in science writing and as a medical industry analyst. He has been a senior director of several large regional and national cancer testing laboratories. The senior editor is a doctoral level clinical scientist. He has over thirty years of experience in laboratory testing and instrument and reagent development technology, as well as extensive experience in senior level positions in biotech and medical service companies.

Some of the statistical information was taken from Biotechnology Associates' databases and from TriMark' s private data stores. The information set forth in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy adequacy or completeness of any information, omission or for the results obtained by the use of such information.

TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects and Sector Snapshots that we publish annually. We extract relevant data and analytics from TriMark' s research of the past three years as part of this data collection. We also extract qualified data feeds from e-questionnaire responses and primary research responses for this compilation.

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government-affiliated trade releases, and other published information as part of our secondary research materials.

The information is then analyzed and translated by the Industry Research Group into a Trimark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations. The report conclusions are verified through intensive interviewing of top-ranking companies in the industry.